AZD 6738

Drug Profile

AZD 6738

Alternative Names: AZD-6738

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Royal Marsden Hospital
  • Class Antineoplastics; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Gastric cancer; Non-small cell lung cancer; Solid tumours
  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Lymphoid leukaemia

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 13 Jan 2017 AstraZeneca plans a phase I trial in Head and neck cancer (Neoadjuvant treatment) in USA, France and United Kingdom (NCT03022409)
  • 15 Nov 2016 AstraZeneca presents results from a phase I/II trial at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top